Induction Therapy With Gefitinib Followed by Chemotherapy With Docetaxel and Cisplatin and Intercalated Gefitinib in NSCLC Stages II-IIIB With Activating EGFR Mutation - A Single Arm Phase II Trial

Trial Profile

Induction Therapy With Gefitinib Followed by Chemotherapy With Docetaxel and Cisplatin and Intercalated Gefitinib in NSCLC Stages II-IIIB With Activating EGFR Mutation - A Single Arm Phase II Trial

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms NeoIntercal
  • Most Recent Events

    • 16 Aug 2017 Status changed from recruiting to discontinued.
    • 10 Jun 2017 Biomarkers information updated
    • 17 Feb 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top